Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer

Inclusion Criteria: * provision of informed consent * clinical stage IIA\~IIIC * histologically proven HR+ invasive breast cancer * women defined as postmenopausal according to NCCN guideline * plan to accept the neoadjuvant (pre operational) chemotherapy treatment Exclusion Criteria: * clinical evidence of metastatic disease * bilateral oophorectomy; * radiation of the ovaries * patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements * patients who accepted anti-cancer treatment before * previous hormonal therapy as adjuvant treatment for non-cancer disease * patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop * previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied * treatment with a non-approved or experimental drug during 1 month before entry into the study * history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin) * leukopenia and/or thrombocytopenia * history of ocular fundus diseases * history of thromboembolic diseases * history of osteoporotic fractures